Clinical bottom line
Emerging therapies for eosinophilic esophagitis (EoE) are expanding beyond traditional topical corticosteroids and dietary management, with biologics such as dupilumab showing promising efficacy in reducing eosinophilic inflammation and improving symptoms. Recent clinical guidelines incorporate these novel agents, reflecting a shift toward targeted immunomodulation. However, long-term safety, cost-effectiveness, and optimal patient selection remain areas requiring further study. Current evidence supports integrating emerging therapies into individualized treatment plans, particularly for patients refractory to conventional approaches (Meek et al., 2023; Dellon et al., 2025).
What the evidence shows
Meek et al. (2023) review recent advances in pharmacotherapy for EoE, highlighting biologic agents targeting interleukin pathways (IL-4, IL-13) such as dupilumab, which have demonstrated significant histologic and symptomatic improvement in randomized controlled trials.
Dellon et al. (2025) provide updated ACG clinical guidelines endorsing the use of dupilumab for patients with moderate to severe EoE, especially those with inadequate response to topical steroids or dietary therapy. The guidelines emphasize a multidisciplinary approach and monitoring for adverse effects.
Greuter et al. (2020) discuss the evolving therapeutic landscape, noting that monoclonal antibodies and small molecules targeting eosinophil recruitment and activation pathways offer potential for disease modification.
Natale et al. (2026) focus on pediatric EoE, underscoring the promise of emerging treatments to improve quality of life and reduce steroid exposure, while calling for more pediatric-specific trials.
Chowdhury et al. (2026) present a systematic review and meta-analysis comparing budesonide and dupilumab, finding that while both reduce eosinophilic infiltration, dupilumab may provide superior symptom relief and sustained remission.
Lucendo et al. (2020) summarize current and investigational pharmacologic options, highlighting the need for personalized treatment algorithms based on disease severity and patient preference.
Caveats and uncertainty
Long-term safety data for biologics in EoE are limited, with potential risks including immunosuppression and hypersensitivity.
High costs and insurance coverage variability may restrict access to novel therapies.
Optimal timing and sequencing of emerging agents relative to established treatments remain unclear.
Heterogeneity in clinical trial endpoints complicates direct comparisons between therapies.
Real-world effectiveness and adherence outside controlled trial settings require further evaluation.
Pediatric data are less robust, necessitating cautious extrapolation from adult studies.
How this may change practice
Clinicians should consider biologic therapies such as dupilumab for patients with moderate to severe EoE who do not respond adequately to topical corticosteroids or dietary interventions.
Integration of emerging therapies may reduce reliance on chronic steroid use and its associated adverse effects.
Multidisciplinary collaboration including allergists, gastroenterologists, and dietitians will optimize individualized care.
Monitoring protocols should be established to assess treatment response and detect adverse events.
Ongoing research and evolving guidelines will inform best practices and expand therapeutic options.